A new study shows that an important drug used in the treatment of malignant melanoma has little effect on the melanoma cells themselves. Instead, it activates immune-system cells to fight the disease.
Schering-Plough/Merck Pharmaceuticals (SPM) announced that the New Drug Application filing for loratadine/montelukast has been accepted by the U.S. Food and Drug Administration (FDA) for standard review.
In the September 15th issue of Genes & Development, Drs. Richard T. Williams, Willem den Besten, and Charles J. Sherr at Howard Hughes Medical Institute, St. Jude Children?s Research Hospital in Memphis TN, lend new insights into how an aggressive form of acute lymphoblastic leukemia (ALL) develops, and how sensitivity to the targeted chemotherapeutic drug, imatinib, can be diminished through interactions between tumor cells and the host microenvironment.
Data from a new Mayo Clinic study suggest that dietary therapy using flaxseed can decrease hot flashes in postmenopausal women who do not take estrogen. The findings from the pilot study are published in the summer 2007 issue of the Journal of the Society for Integrative Oncology.
A drug that shuts down a critical cell-signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows.
Two University of Virginia School of Medicine researchers have been awarded grants from the National Institute of Allergy and Infectious Diseases to develop treatments and tests for some rapidly emerging trouble spots in the area of gastrointestinal diseases.
Funded by a $1.5 million grant from the National Institutes of Health, scientists at Binghamton University, State University of New York, hope to understand how the malaria parasite Plasmodium falciparum evolved resistance to the once-effective medication chloroquine.
Researchers in Cincinnati and Louisville report that immunosuppressive risks associated with facial transplantation may be lower than thought, possibly making the procedure a safer option for people who have suffered severe facial injuries.
Not everyone needs a genetic test before taking the cancer drug irinotecan, and the U.S. Food and Drug Administration should modify its prescription guidelines to say so, according to researchers at the University of North Carolina at Chapel Hill.
A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia.